XXII (XXII) Stock Price & Analysis
XXII (XXII) rose 7.46% to USD 2.45 as of September 8, 2026 at 09:35 UTC, according to Nexqual real-time market data.
XXII last closed at USD 2.45; the session ranged USD 2.28–2.5 on volume of 30,770 shares. Market capitalization is —, with a 52-week range of USD 2.27–646.5 (NCM). Source: Nexqual, September 8, 2026 at 09:35 UTC.
Key Statistics (as of September 8, 2026 at 09:35 UTC)
| Price | USD 2.45 |
|---|---|
| Change | ▲ 7.46% (up) |
| Previous Close | USD 2.45 |
| Open | USD 2.45 |
| Day Range | USD 2.28 – 2.5 |
| 52-Week Range | USD 2.27 – 646.5 |
| Volume | 30,770 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (XXII)
Nexqual's technical model rates XXII "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 09:35 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 30.03 (neutral) |
| vs SMA50 | Below (USD 3.93) |
| MACD | -0.57 (negative) |
From XXII's Latest SEC 10-K Filing (filed 2026-03-26)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TVRD | Tvardi Therapeutics, Inc. | USD 1.91 | ▲ 1.6% |
| DOGP | Dogecoin Cash Inc. | USD 0.01 | ▲ 6.94% |
| CANN | TREES Corporation | USD 0.02 | ▲ 15.88% |
| CVSI | CV Sciences, Inc. | USD 0.02 | ▲ 0% |
| IGC | IGC Pharma, Inc. | USD 0.3 | ▼ 0.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:35 UTC. This page is informational and not investment advice.